June 2023

Sustained low functional impairment in axial spondyloarthritis (axSpA): Which are the primary outcomes that should be targeted to achieve this?

Arthritis Research & Therapy (2023) 25:70 https://pubmed.ncbi.nlm.nih.gov/37118833/

This real-world study showed that sustained BASDAI <3 may be a valid and feasible target for a treat-to-target strategy in AxSpA, having function as treatment goal.

more…

Effect of Body Mass Index on Treatment Response of Biologic/ Targeted-Synthetic DMARDs in Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Axial Spondyloarthritis. A Systematic Review

Autoimmunity Reviews 22 (2023) 103357

The study demonstrated that obesity is a factor that could play a role in treatment decision-making in people living with inflammatory arthritis (IA). It appears that efficacy of TNFi is affected by patients’ weight/BMI in all forms of IA, while this is not the case for TCZ and ABA in RA, as well for IL-17 and IL-23 inhibitors in PsA.

more…

Two‑Year Imaging Outcomes from a Phase 3 Randomized Trial of Secukinumab in Patients with Non‑Radiographic Axial Spondyloarthritis

Arthritis Res Ther. 2023;16;25(1):80 doi 10.1186/s13075-023-03051-5

Braun et al. studied a large cohort of patients with nr-axSpA, that demonstrated a secukinumab reduced SI joint inflammation (BME), this reduction was sustained over 104 weeks, from an overall low baseline level of spinal inflammation or structural damage.

more…

JAK Inhibitors and the Risk of Malignancy: A Meta-analysis Across Disease Indications

Ann Rheum Dis. 2023;2023-224049 doi: 10.1136/ard-2023-224049 Epub ahead of print

The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.

more…

Baricitinib Improves Bone Properties and Biomechanics in Patients with Rheumatoid Arthritis – Results of the Prospective Interventional BARE BONE Trial

Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print

The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.

more…

May 2023

A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report

Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164

Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects

more…

When to Start Secukinumab Treatment in Patients with Axial Spondyloarthropathy: Before or After Anti-TNFα Treatment?

Reumatol Clin. 19 (2023); 175–179 doi 10.1016/j.reumae.2022.03.007

Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.

more…